经乳头胰管支架置入作为远端胰腺切除术后难治性胰瘘的挽救治疗:支持十二指肠乳头梗阻作用的病例系列
该病例系列纳入5例远端胰腺切除术后难治性B级胰瘘患者,定义为经皮引流和药物治疗后高流量(>100 mL/天)持续>3周或新发假性囊肿。所有患者接受内镜逆行胰造影(ERP)并置入经乳头胰管支架,技术成功率和临床成功率均为100%,无操作相关并发症。结果支持十二指肠乳头梗阻在胰瘘持续中的作用,并建议对标准措施无效的高流量胰瘘早期考虑ERP。
要点
- ERP联合胰管支架置入对远端胰腺切除术后难治性B级胰瘘技术成功率和临床成功率均为100%。
- 临床成功定义为72小时内瘘流量下降>75%且4周内完全闭合,5例患者均达到。
- 无操作相关并发症,支持ERP作为微创挽救治疗。
核心结论
- ERP联合胰管支架置入是远端胰腺切除术后难治性胰瘘高效、微创的挽救治疗。
- 结果支持十二指肠乳头梗阻在胰瘘持续中的病理生理作用。
- 建议对标准措施无效的高流量胰瘘早期考虑ERP。
研究设计与样本
- 病例系列研究,纳入5例远端胰腺切除术后难治性B级胰瘘患者。
- 难治性定义:经皮引流和药物治疗后高流量(>100 mL/天)持续>3周或新发假性囊肿。
- 所有患者接受ERP,关键操作目标为穿过乳头并置入支架至残端胰管以 bypass 潜在梗阻并实现内减压。
主要发现
- ERP联合经乳头支架置入技术成功率为100%(5/5)。
- 临床成功(72小时内瘘流量下降>75%且4周内完全闭合)率为100%(5/5)。
- 无操作相关并发症发生。
关键数值与推荐
- 难治性胰瘘定义:经皮引流和药物治疗后高流量(>100 mL/天)持续>3周或新发假性囊肿。
- 临床成功定义:72小时内瘘流量下降>75%且4周内完全闭合。
临床怎么用
- 对远端胰腺切除术后难治性高流量胰瘘,可考虑ERP联合胰管支架置入作为挽救治疗。
- 操作关键在于穿过十二指肠乳头并置入支架至残端胰管,实现内减压。
- 建议在标准措施无效的高流量胰瘘管理中早期考虑ERP。
局限性
- 样本量小(5例),为病例系列研究,证据级别有限。
- 结果需更大样本研究验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Endoscopic retrograde pancreatography (ERP) with pancreatic duct stenting is a recognized intervention for pancreatic fistulas. However, its application as a salvage therapy for refractory postoperative pancreatic fistula (POPF) after distal pancreatectomy (DP) remains less defined, particularly when guided by the hypothesis that duodenal papilla obstruction perpetuates the fistula. This study evaluated the efficacy of ERP with stenting for refractory POPF after DP and investigated the role of papilla morphology. METHODS: Five patients with refractory Grade B POPF after DP were included. Refractoriness was defined as persistent high-output (> 100 mL/day) for > 3 weeks despite percutaneous drainage and medical therapy or newly developed pseudocysts. All patients underwent ERP. The key procedural goal was to traverse the papilla and place a stent into the pancreatic duct of the remnant to bypass any potential obstruction and achieve internal decompression. RESULTS: ERP with trans-papillary stent placement was technically successful in all five patients (100%). Clinical success, defined as a dramatic reduction in fistula output (> 75%) within 72 h and complete fistula closure within 4 weeks, was achieved in all 5 patients (100%). No procedure-related complications occurred. CONCLUSION: In this case series, ERP with pancreatic duct stenting is a highly effective and minimally invasive salvage therapy for refractory POPF after DP. Its consistent success provides strong clinical support for the pathophysiological role of duodenal papilla obstruction. We propose that ERP should be considered early in the management algorithm for high-output POPF that fails to resolve with standard measures.
引用
- Zeng JT, Luo ZH, Dou L, et al. Transpapillary pancreatic duct stenting as a salvage therapy for refractory pancreatic fistula after distal pancreatectomy: a case series supporting the role of duodenal papilla obstruction. Surg Endosc. 2026. PMID: 41792492. doi:10.1007/s00464-026-12695-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。